Literature DB >> 23725755

STAT pathway in the regulation of zoledronic acid-induced apoptosis in chronic myeloid leukemia cells.

Hatice Demet Kiper1, Burcin Tezcanli Kaymaz, Aysun Adan Gokbulut, Nur Selvi, Cigir Biray Avci, Buket Kosova, Guniz Iskender, Melis Kartal Yandim, Cumhur Gunduz, Fahri Sahin, Yusuf Baran, Guray Saydam.   

Abstract

In this study, we aimed to evaluate the cytotoxic and apoptotic effects of zoledronic acid on K562 chronic myeloid leukemia (CML) cells and to examine the roles of STAT genes on zoledronic acid-induced apoptosis. The results showed that zoledronic acid decreased proliferation, and induced apoptosis in K562 cells in a dose- and time-dependent manner. mRNA and protein levels of STAT3, -5A and -5B genes were significantly reduced in zoledronic acid-treated K562 cells. These data indicated that STAT inhibition by zoledronic acid may be therapeutic in CML patients following the confirmation with clinical studies.
Copyright © 2013 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Chronic myeloid leukemia; STATs; Zoledronic acid

Mesh:

Substances:

Year:  2013        PMID: 23725755     DOI: 10.1016/j.biopha.2013.04.006

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  5 in total

1.  Expression and functions of the STAT3-SCLIP pathway in chronic myeloid leukemia cells.

Authors:  Li Li; Yanlong Zheng; Wanzhuo Xie
Journal:  Exp Ther Med       Date:  2016-10-03       Impact factor: 2.447

2.  Synergistic suppression of human breast cancer cells by combination of plumbagin and zoledronic acid In vitro.

Authors:  Han Qiao; Ting-yu Wang; Wei Yan; An Qin; Qi-ming Fan; Xiu-guo Han; Yu-gang Wang; Ting-ting Tang
Journal:  Acta Pharmacol Sin       Date:  2015-08-03       Impact factor: 6.150

3.  Bisphosphonates enhance EGFR-TKIs efficacy in advanced NSCLC patients with EGFR activating mutation: A retrospective study.

Authors:  Chu-Ying Huang; Li Wang; Cheng-Jun Feng; Ping Yu; Xiao-Hong Cai; Wen-Xiu Yao; Yong Xu; Xiao-Ke Liu; Wen-Jiang Zhu; Yan Wang; Jin Zhou; You Lu; Yong-Sheng Wang
Journal:  Oncotarget       Date:  2016-10-11

4.  Zoledronic acid inhibits the growth of leukemic MLL-AF9 transformed hematopoietic cells.

Authors:  Emanuela Chiarella; Bruna Codispoti; Annamaria Aloisio; Emanuela G Cosentino; Stefania Scicchitano; Ylenia Montalcini; Daniela Lico; Giovanni Morrone; Maria Mesuraca; Heather M Bond
Journal:  Heliyon       Date:  2020-06-05

5.  Low-dose zoledronate for the treatment of bone metastasis secondary to prostate cancer.

Authors:  Elie Akoury; Pouyan Ahangar; Antone Nour; Jacques Lapointe; Karl-Philippe Guérard; Lisbet Haglund; Derek H Rosenzweig; Michael H Weber
Journal:  Cancer Cell Int       Date:  2019-02-08       Impact factor: 5.722

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.